AA
AUTL

ALPS Advisors’s Autolus Therapeutics AUTL Stock Holding History

ALPS Advisors’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-124,606
Closed -$203K – 1019
2025
Q3 		$203K Sell
124,606
-19,008
-13% -$37.1K ﹤0.01% 1007
2025
Q2 		$327K Sell
143,614
-56,095
-28% -$92.8K ﹤0.01% 904
2025
Q1 		$310K Sell
199,709
-15,481
-7% -$31.4K ﹤0.01% 893
2024
Q4 		$506K Buy
+215,190
New +$727K ﹤0.01% 602
2023
Q4 		– Sell
-128,147
Closed -$299K – 966
2023
Q3 		$299K Buy
128,147
+927
+0.7% +$2.64K ﹤0.01% 883
2023
Q2 		$303K Buy
+127,220
New +$302K ﹤0.01% 866
2022
Q4 		– Sell
-49,657
Closed -$106K – 1030
2022
Q3 		$106K Sell
49,657
-4,274
-8% -$12.7K ﹤0.01% 1028
2022
Q2 		$153K Sell
53,931
-39,502
-42% -$120K ﹤0.01% 1006
2022
Q1 		$390K Buy
93,433
+9,051
+11% +$38.1K ﹤0.01% 492
2021
Q4 		$438K Buy
+84,382
New +$506K ﹤0.01% 569

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

ALPS Advisors's AUTL Position: Q4 2025 in Review

ALPS Advisors sold out of Autolus Therapeutics (AUTL) in Q4 2025, closing a stake of 124,606 shares — an estimated $203K sold.

ALPS Advisors first reported a position in AUTL in Q4 2021 and held it in 10 quarters. The position peaked at $506K in Q4 2024. 89 funds tracked by Wall St. Rank hold AUTL as of Q4 2025.

  • ALPS Advisors reported no remaining Autolus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • ALPS Advisors sold 124,606 Autolus Therapeutics shares in Q4 2025, an estimated $203K.
  • ALPS Advisors first reported a position in Autolus Therapeutics in Q4 2021 and held it in 10 quarters.
  • ALPS Advisors's Autolus Therapeutics position peaked at $506K in Q4 2024.
  • 89 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2025.

Based on ALPS Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.